Across TCGA pan-cancer cohorts, MIR409 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MIR409 data layer compared with 11 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher MIR409 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR409 expression acts as an unfavorable survival marker.
COAD and BLCA are the cancer types where MIR409 Mutation most reproducibly stratifies survival.